secwatch.observer — SEC 8-K summary
======================================

Issuer:     Advanced Biomed Inc. (ADVB)
CIK:        0001941029
Form:       8-K
Filed at:   2025-12-30T23:59:59+00:00
Accession:  0001213900-25-126584
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Advanced Biomed sells Hong Kong subsidiary for $23K; moves clinical trials to Taiwan
--------------------------------------------------------------------------------

- Sold 100% of Advanced Biomed (HK) Limited and all IP of Shanghai Sglcell Biotech Co., Ltd. for US$23,000.
- Transaction closed on December 23, 2025; board unanimously approved.
- CEO cites evolving China regulatory requirements on clinical trials and data as reason for divestiture.
- All clinical trials will now be centralized and conducted through the Taiwan subsidiary.
- Buyer Wei Ha Hui is an unrelated third party.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1941029/000121390025126584/0001213900-25-126584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1941029/000121390025126584/ea0271157-8k_advanced.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-126584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer